AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $499.03 ($481.91–$504.15, $4.74M total) across 15 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 9, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosure may trigger short‑term selling pressure but likely has limited long‑term effect given the insider's remaining holdings.

02

Market read

Primary insider sale provides fresh data for traders monitoring UTHR; modest downside risk.

03

What to watch

The sale was executed over many small trades, possibly to avoid market impact; the insider retains a large stake.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑08 filing released 2026‑09‑09

Background

Form 4 filings disclose insider transactions; a $4.7M sale by the CEO is a primary source of new information.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO/Chairperson Martine Rothblatt sold $4.74M of United Therapeutics shares via a pre‑arranged 10b5‑1 plan on 2026‑09‑08.

Expected impact

Potential modest downside of 1‑2% over the next few days.

Evidence & confidence

The sale represents a significant portion of the insider's holdings and is disclosed through a Form 4, indicating a direct market impact.

Market effects

Sector

Minimal; biotech sector unlikely to be broadly affected.

Regional

U.S. market only; no regional ripple.

Global

Low; isolated to United Therapeutics.

Counterpoint

What could challenge this read

Insider sell could be routine liquidity management under a 10b5‑1 plan, not a bearish signal.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing and commercializing organ transplantation therapies.

  • person
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics, insider selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min